Proteome Sciences Plc ("the Company")
18 April 2007
Onconome Inc. to Use ProteoSHOP® for Cancer Biomarkers
Proteome Sciences plc ("Proteome") is pleased to announce that it is to apply
its ProteoSHOP® proteomics toolbox to analyse prostate and colon cancer
materials provided by Seattle based Onconome Inc. ("Onconome").
Proteome has a strong track-record in the discovery and validation of cancer
biomarkers and will apply its 2-dimensional gel western blotting technology to
further characterise diagnostic antibodies developed by Onconome for the
diagnosis and prognostic monitoring of patients with prostate and colon
cancers. In addition Proteome will perform new biomarker discovery using
Onconome's materials on its high-throughput 2-dimensional gel electrophoresis
platform and using its patented isobaric Tandem Mass Tags® for gel-free
analyses.
Under the terms of the collaboration Proteome will receive research funding for
the provision of ProteoSHOP® services.
Commenting on the collaboration H. Raymond Cairncross, Co-Founder and Chief
Executive Officer of Onconome Inc. said:
"As a company dedicated to the discovery, development and commercialization of
protein biomarkers for the early detection of prostate, colon and other types
of cancers and life-threatening diseases, it is critical that we collaborate
with companies highly skilled and experienced in the proteomics field. We feel
we have found such a partner in Proteome Sciences and look forward to a
mutually productive and profitable relationship."
Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome
Sciences said:
"We are pleased to announce this ProteoSHOP® deal building on the technological
and commercial progress made in the last 12 months. Our unique combination of
proteomics solutions for biomarker discovery and validation, linked to our
considerable experience in oncology provides Onconome with access to the tools
needed for further characterisation of their prostate and colon cancer
biomarkers.
This collaboration reflects a growing need within the diagnostics and
pharmaceutical industries for external sourcing of well characterised and
validated protein biomarkers which ProteoSHOP® was designed to support. With a
portfolio of well characterised biomarkers across a range of diseases and the
patented technologies within ProteoSHOP® we are ideally placed to become the
partner of choice for protein biomarker discovery projects."
Ends
Notes to editors:
Proteome Sciences plc
Proteome Sciences, a global leader in applied proteomics, uses high sensitivity
proprietary technologies to detect differentially expressed proteins in
diseases. The protein biomarkers discovered in body fluids or tissues are
validated, developed and commercialised as diagnostic, prognostic or
therapeutic products through strategic alliances and out-licensing.
Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers.
Sensitizer® chemical mass tags have been developed separately as a series of
stand-alone reagents.
For further information please visit www.proteomics.com.
Proteome Sciences plc
Dr. Ian Pike, Business Development Director
Email: ian.pike@proteomics.com
Christopher Pearce, Chief Executive Officer
Email: christopher.pearce@proteomics.com
Tel: +44 (0)1932 865065
Onconome, Inc.
Onconome, Inc. (Seattle, WA) was incorporated in 2000 as a biomedical company
committed to the discovery and commercialization of products for the early
detection of prostate, colon, and other types of cancer and life-threatening
human diseases. Through its licensing arrangements with both Johns Hopkins
University School of Medicine and the University of Pittsburgh, Onconome has
obtained exclusive, worldwide rights to the use and development of numerous
protein markers for the early diagnosis of cancer as well as for drug screening
and in vivo imaging. Under a Contract Research Agreement, Onconome funds the
discovery and development of these biomarkers at Johns Hopkins. University.
For more information, visit the company's Web site at www.onconome.com
Onconome, Inc.
Erick Rabins, Managing Director, Business Development
Email: erabins@onconome.com
Ray Cairncross, Co-Founder & Chief Executive Officer
Email: rcairncross@onconome.com
Tel: 206-268-3500
Public Relations for Proteome Sciences
IKON Associates
Adrian Shaw
Tel: +44 (0)1483 535102
Mobile: +44 (0)797 9900733
Email: adrian@ikonassociates.com